LSH
Director Trades
| Date | Director | Value |
|---|
Company News
Lifespot Health rebrands to InhaleRx, pushes development of Medihale inhaler
Australian medicinal cannabis device company Lifespot Health (ASX: LSH) has officially changed its name to InhaleRx (ASX: IRX), with the change to take effect on Wednesday. The new moniker has been termed a “natural evolution” for the company, which announced a strategic change of direction last year from promoting skin cancer screening technology to the […]
Lifespot Health reveals new R&D strategy amid board shake-up
Medical cannabis device developer Lifespot Health (ASX: LSH) has announced a revised research and development strategy prioritising US Food and Drug Administration (FDA) approval of its Medihale cannabinoid inhaler system. The news follows several changes to the company’s board including the most recent appointment of a new chairman, Sean Williams. Lifespot today revealed its chosen […]
Lifespot Health appoints cannabis specialists to board of directors
Australian medicinal cannabis device company Lifespot Health (ASX: LSH) has appointed two non-executive directors to its board to help execute a strategy of delivering innovative medication systems and therapies to market. Cannabinoid specialists Dr Andrew Saich and Darryl Davies have a wealth of combined industry experience and are believed to be well-qualified to drive the […]
Lifespot Health appoints Canadian advisor to take medical cannabis technology to the world stage
Medical cannabis device developer Lifespot Health (ASX: LSH) has appointed Canadian investment fund Ela Capital as its corporate advisor to assist with the commercialisation of its technologies in the global cannabis market. Toronto-based Ela Capital became a major shareholder of Lifespot at the start of the year after investing close to $800,000 in a capital […]
Lifespot Health launches Medihale sealed pod inhaler to medical cannabis market in Australian first
Lifespot Health (ASX: LSH) has achieved first sales of its medical cannabis inhaler to Australian patients under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). The company has officially launched its Medihale sealed pod inhaler device in Melbourne, with the first patient group using the device, pod and third-party EC Pharma’s cannabidiol e-liquid. Lifespot […]
Lifespot Health generates revenue from Medihale medicinal cannabis inhaler device
Inhaled medical cannabis device developer Lifespot Health (ASX: LSH) ended the December 2020 quarter with its first revenue from sales of its Medihale inhaler device. Sales of the device generated $73,000 in cash to Lifespot, while operating expenditure was $207,000. Operating expenditure comprised an outlay of $33,000 towards ongoing R&D of Medihale and Lifespot’s other […]
Lifespot Health reveals investment from major Canadian cannabis fund
Lifespot Health (ASX: LSH) has announced a significant investment by major Canadian cannabis investment fund Ela Capital, marking a great achievement for the Australian cannabis industry as well as providing the necessary boost for the accelerated development of its Medihale vape device. Earlier this month, Lifespot completed the issue of 22.3 million shares as part […]
Medical cannabis expert boosts Lifespot Health leadership ahead of vape pen trials
Lifespot Health (ASX: LSH) is further enhancing its leadership team and topping up cash reserves as it advances the development of its medical cannabis inhaler device program it claims will “significantly evolve the treatment options for patients both in Australia and overseas”. Investors are also seeing the value as Lifespot Health leads the way in […]
Lifespot Health creates self-managed biosensor system to combat metabolic syndrome and diabetes
Medical diagnostics and technology company Lifespot Health (ASX: LSH) has announced the highly-anticipated launch of its patient self-management system for metabolic syndrome and diabetes. The system is the result of 3 years of laborious development and sets the stage for Lifespot to start its “sales offensive” in one of the most rapidly emergent markets in […]
